Preparation and characterization of human HIV type 1 neutralizing reference sera. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Preparation and characterization of human HIV type 1 neutralizing reference sera.

AIDS Res Hum Retroviruses. 1995 Jul;11(7):783-7. Unique Identifier : AIDSLINE MED/96053840
Vujcic LK; Quinnan GV Jr; Center for Biologics Evaluation and Research, Food and Drug; Administration, Rockville, Maryland 20852-1448, USA.

Abstract: Reference neutralizing antibody (NA) reagents are needed for laboratories to be able to compare results of neutralization assays that will be used to monitor HIV-1 vaccine recipients. In an effort to establish such reference reagents two asymptomatic, seropositive patients were identified with medium to high amounts of cross-reactive NA activity against a number of HIV-1 strains. Sera obtained from each individual at three or four sequential phlebotomies were pooled, and the two pools were each distributed in > 3000 aliquots into glass ampoules and lyophilized, and the ampoules were flame sealed. An HIV-1 antibody-negative reference serum was prepared in a similar fashion after pooling serum from four individuals. Ampoules were tested for uniformity of fill, sterility, moisture content, residual oxygen, stability, infectivity, and presence of antibody. An international collaborative study was conducted to determine the potency of the samples in six laboratories, each using their own neutralization assays and reagents. The results indicated reasonable consistency between laboratories and that both sera have sufficient titers against a variety of strains for use as reference reagents. These reference sera have been included in the World Health Organization (WHO) AIDS Reagent Project and are available through the three AIDS reagent repositories.
Keywords: Acquired Immunodeficiency Syndrome/BLOOD/*IMMUNOLOGY/VIROLOGY AIDS Vaccines/*IMMUNOLOGY Bias (Epidemiology) Cell Line Comparative Study Enzyme-Linked Immunosorbent Assay/METHODS/STANDARDS Human HIV Antibodies/*BLOOD HIV Seropositivity/BLOOD/*IMMUNOLOGY/VIROLOGY HIV-1/*IMMUNOLOGY Monitoring, Immunologic/METHODS/STANDARDS Neutralization Tests Quality Control Reference Values Reproducibility of Results JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/blood/KWDimmunology/virologyaidsvaccines/KWDimmunologybias(epidemiology)celllinecomparativestudyenzyme-linkedimmunosorbentassay/methods/standardshumanhivantibodies/KWDbloodhivseropositivity/blood/KWDimmunology/virologyhiv-1/KWDimmunologymonitoring,immunologic/methods/standardsneutralizationtestsqualitycontrolreferencevaluesreproducibilityofresultsjournalarticle
960130
M9610758

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .